Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

Journal: Nature Medicine

Published: 2019-12-02

DOI: 10.1038/s41591-019-0654-5

Affiliations: 25

Authors: 36

Go to article
Institutions Share
Broad Institute of MIT and Harvard, United States of America (USA) 0.22
Dana-Farber Cancer Institute (DFCI), United States of America (USA) 0.12
German Consortium of Translational Cancer Research (DKTK), Germany 0.09
Essen University Hospital, Germany 0.08
Department of Dermatology, JGU, Germany 0.06
Harvard Medical School (HMS), United States of America (USA) 0.04
Eli Lilly and Company, United States of America (USA) 0.03
Charité Department of Dermatology, Venerology and Allergology, Germany 0.03
Department of Dermatology, UR, Germany 0.03
Department of Dermatology, Uni Tübingen, Germany 0.03
Department of Dermatology, Uni Freiburg, Germany 0.03
Division of Medical Oncology, NKI, Netherlands 0.03
Massachusetts General Hospital (MGH), United States of America (USA) 0.03
Department of Dermatology, UZH, Switzerland 0.03
Faculty of Medicine, UOA, Greece 0.03
Clinic for Dermatology, Allergology and Venerology, MHH, Germany 0.03
Skin Cancer Center Hannover (HTZH), MHH, Germany 0.03
German Cancer Research Center in the Helmholtz Association (DKFZ), Germany 0.02
TUM Department of Internal Medicine III (Hematooncology/Oncology), Germany 0.01
University Medical Centre Mannheim (UMM) at Medical Faculty Mannheim, Uni Heidelberg, Germany 0.01
University Hospital Carl Gustav Carus Dresden, TU Dresden, Germany 0.01
National Center for Tumor Diseases (NCT) Heidelberg, Germany 0.01
Harvard Program in Biophysics, United States of America (USA) 0.01
University Hospital of Münster (UKM), WWU, Germany 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER